NEW HEART HEALTH PATENTS FOR VITAMIN K2 Monday 20 December 2010 PDF Print According to new grants of patent applications vitamin K2 shows more promise in heart health. NattoPharma ASA, the Norwegian supplier of Vitamin K2 (trade marked as MenaQ7) has successfully defended two of its European patent applications relating to new uses of vitamin K in treating or preventing cardiovascular diseases before the European Patent Office. The grant of these patents is expected to be published in the first half of 2011. The first patent application, EP 06076172.3, discloses and claims the use of vitamin K in medicaments or food supplements for reversing calcification of blood vessels. The second patent application, EP 03790959.5, discloses and claims the use of vitamin K in medicaments or food supplements for preventing age-related stiffening of arteries, not associated with atherosclerosis. Two major epidemiological studies - with over 21,000 people - showed that taking Vitamin K2, in the form of menaquinone-7, will significantly reduce the risk of developing or dying from cardiovascular disease. The Rotterdam Study (an analysis of around 5000 individuals) showed a strong link between long-term intake of vitamin K2 (menaquinone-7) and a reduced risk of coronary heart disease (CHD). The findings of the study suggested the relative risk of mortality from CHD was reduced where dietary intake of menaquinone-7 was higher. In the Prospect-EPIC cohort, consisting of 16,057 postmenopausal women, researchers observed an inverse association between vitamin K2 and risk of CHD. Increased intakes of vitamin K2, but not vitamin K1, may decrease the risk of coronary heart disease in women, says this study. For every 10 microgram increase in the amount of vitamin K2 consumed, researchers from the Netherlands report a 9 per cent reduction in the risk of developing coronary heart disease (CHD). This association was mainly due to vitamin K2 subtypes MK-7, MK-8 and MK-9. Vitamin K1 intake was not significantly related to CHD. Springfield Nutraceuticals MenaQ7* vitamin K2 brand has been available in the UK for some while now from Independent Health Food Stores and www.nutricentre.com or by calling 0800 587 2290. Priced at £18.95 for 60 small tablets with 45mcg vitamin K2. For more information please visit the website: www.menaq7.com *MenaQ7 is a daily supplement formulated using natural vitamin K2 (MK-7) derived from Japanese natto, a fermented soy product. ~ ends ~ Further press info from email@example.com – 05602 525124 This press release was distributed by ResponseSource Press Release Wire on behalf of Partners in PR Ltd in the following categories: Men's Interest, Health, Women's Interest & Beauty, Medical & Pharmaceutical, for more information visit http://pressreleasewire.responsesource.com/about.